BHCA little sideways still on the 4 hour, watching here to see if we can get moving, 4 hour STOCH RSI alarm set.
−1.39CHF
−507.57 MCHF
7.51 BCHF
356.59 M
About BAUSCH HEALTH
Sector
CEO
Thomas J. Appio
Headquarters
Laval
Website
Employees (FY)
20.27 K
Founded
1994
FIGI
BBG006TLX225
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
$BHC - LongThis stock has horrifically bad spreads, i usually stay away from trash like this but reviewing trading data from this month i'm seeing extremely big activity behind this stock. I also checked around and apparently Jim Cramer is bearish this stock within the same month as said same extremely trading
Looking for a breakoutThis is my idea for a short term target. the price is ranging. Once it breaks out the horizontal channel, it will have potential to go up until the mentioned target.
BHCThere’s a gap around $2.50.
5Y
RSI is overbought.
Prediction: I expect this to continue down to around 2.50.
BHC - Diagonal Double BottomDiagonal double bottom along strong downtrend line
This double bottom may push price up within this falling wedge structure I have plotted
If it breaks the upper line further increases may be seen
RetracedWe have retraced the complete decline since 10th February. As the overall trend remains bearish we may expect a further fall now. At 2 there is a major resistance level now.
BHC - bullish setup weeklyLong-term, perfect buy setup.
Impulse as a leading diagonal, correction as a flat. Wave 3 is likely an extended one.
Good luck!
BHC - Short shortThis is a simple setup- it feels like a 50% retracement from the recent high
Technicals
1) the trend line was crossed
2) the moving average crossed below and has stayed there for a few days
Targeting a move to S1 ($27) - approx. a 15% move from today's close ($31)
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VRX is 21.44 CHF — it has increased by 3.68% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange BAUSCH HEALTH stocks are traded under the ticker VRX.
BAUSCH HEALTH is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
VRX stock is 4.62% volatile and has beta coefficient of 1.45. Check out the list of the most volatile stocks — is BAUSCH HEALTH there?
VRX earnings for the last quarter are 1.00 CHF per share, whereas the estimation was 0.85 CHF resulting in a 17.62% surprise. The estimated earnings for the next quarter are 0.87 CHF per share. See more details about BAUSCH HEALTH earnings.
BAUSCH HEALTH revenue for the last quarter amounts to 2.08 B CHF despite the estimated figure of 1.99 B CHF. In the next quarter revenue is expected to reach 1.96 B CHF.
Yes, you can track BAUSCH HEALTH financials in yearly and quarterly reports right on TradingView.
VRX net income for the last quarter is −33.74 M CHF, while the quarter before that showed −341.66 M CHF of net income which accounts for 90.12% change. Track more BAUSCH HEALTH financial stats to get the full picture.
Today BAUSCH HEALTH has the market capitalization of 2.82 B, it has increased by 1.34% over the last week.
No, VRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BAUSCH HEALTH stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 20.27 K employees. See our rating of the largest employees — is BAUSCH HEALTH on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BAUSCH HEALTH technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BAUSCH HEALTH stock shows the sell signal. See more of BAUSCH HEALTH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BAUSCH HEALTH future price: according to them, VRX price has a max estimate of 14.66 CHF and a min estimate of 6.34 CHF. Read a more detailed BAUSCH HEALTH forecast: see what analysts think of BAUSCH HEALTH and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BAUSCH HEALTH EBITDA is 2.46 B CHF, and current EBITDA margin is 32.71%. See more stats in BAUSCH HEALTH financial statements.